Showing 5031-5040 of 5771 results for "".
- EyeCare Partners Completes Acquisition of Nationwide Visionhttps://modernod.com/news/eyecare-partners-acquires-nationwide-vision/2476871/EyeCare Partners announced it has completed its acquisition of Arizona-based Nationwide Vision. Financial terms of the transaction were not disclosed. Nationwide, headquartered in Chandler, Arizona, operates 89 optometry off
- Rayner Launching RayOne Trifocal Toric at ESCRShttps://modernod.com/news/rayner-launching-rayone-trifocal-toric-at-escrs/2476866/Rayner announced it is launching its RayOne Trifocal Toric fully preloaded IOL at the ESCRS 2019 congress in Paris. With 11% light loss from its patented diffractive design, RayOne Trifocal Toric will give cataract pa
- The American Academy of Ophthalmology and Verana Health Launch Verana Practice Insights to Innovate Patient Carehttps://modernod.com/news/the-american-academy-of-ophthalmology-and-verana-health-launch-verana-practice-insights-to-innovate-patient-care/2476864/The American Academy of Ophthalmology (AAO) and Verana Health announced the launch of Verana Practice Insights, a new tool that aims to enable physicians to improve patient outcomes and provide better care through critical data insights and trends procured from the largest specialty clinical data
- MeiraGTx To Present Clinical Data from Phase 1/2 Trial of AAV-RPE65 at Upcoming Scientific Conferenceshttps://modernod.com/news/meiragtx-to-present-clinical-data-from-phase-1-2-trial-of-aav-rpe65-at-upcoming-scientific-conferences/2476861/MeiraGTx Holdings announced that clinical data updates from the company’s phase 1/2 trial of AAV-RPE65 will be presented at two upcoming medical meetings. The phase 1/2 open-label, multicenter, dose-finding trial evaluated AAV-RPE65 in patients with retinal dystrophy associated with diseas
- CorNeat Vision Completes Preclinical Phase For Synthetic Cornea and Scleral Patchhttps://modernod.com/news/corneat-vision-completes-preclinical-phase-for-synthetic-cornea-and-scleral-patch/2479538/CorNeat Vision announced it has completed the preclinical stage of its cornea implant (CorNeat KPro/Keratoprosthesis) and the first synthetic, non-degradable scleral patch (CorNeat EverPatch). The company’s solutions, which also include a glaucoma drainage device, the CorNeat eShunt, will b
- ProQR Receives Fast Track Designation from FDA for QR-1123 for Autosomal Dominant Retinitis Pigmentosahttps://modernod.com/news/proqr-receives-fast-track-designation-from-fda-for-qr-1123-for-autosomal-dominant-retinitis-pigmentosa/2479540/ProQR Therapeutics announced that it received fast track designation from the FDA for QR-1123, a first-in-class investigational antisense oligonucleotide designed to address the underlying cause of vision loss associated with autosomal dominant retinitis pigmentosa (adRP) due to the P23H mutation
- EyeCare Partners Completes Acquisition of Associated Retinal Consultantshttps://modernod.com/news/eyecare-partners-completes-acquisition-of-associated-retinal-consultants/2476858/EyeCare Partners announced it has completed the acquisition of Associated Retinal Consultants, an ophthalmology provider and one of the largest retina subspecialty practices in the United States. Financial terms of the private transaction were not disclosed. Headquartered in
- NHS England to Fund Novartis’ Gene Therapy Luxturna for Inherited Retinal Diseasehttps://modernod.com/news/nhs-england-to-fund-novartis-gene-therapy-luxturna-for-inherited-retinal-disease/2476855/NHS England announced Wednesday funding for Novartis’ Luxturna (voretigene neparvovec) after agreeing a deal with the company that will provide access to the gene therapy from January 2020. The one-time treatment gained European Commission approval last year for patients with vision loss du
- Genentech to Present Pivitol Data for Satralizumab in Neuromyelitis Optica Spectrum Disorderhttps://modernod.com/news/genentech-to-present-pivitol-data-for-satralizumab-in-neuromyelitis-optica-spectrum-disorder/2476853/Genentech announced that new data across its neuroscience portfolio will be presented at the 35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) from September 11-13 in Stockholm. Presentations include complete phase 3 results from the SAkuraS
- Sight Sciences Raises $56M to Lead the Development of MIGS Market and Procedure-Based Dry Eye Markethttps://modernod.com/news/sight-sciences-raises-56m-to-lead-the-development-of-migs-market-and-procedure-based-dry-eye-market/2476848/Sight Sciences announced the closing of $31 million in Series D Preferred Stock financing. MidCap Financial and Sight Sciences entered into a $25 million debt facility earlier in 2019. The $56 million